AcquisitionOther
GSK plc acquired Nuvalent, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
GSK plc -> Nuvalent, Inc. · $10.6 billion
Acquire multi-product oncology deal with validated ROS1 and ALK inhibitors for NSCLC.
Open source record (SEC) ↗